Gilberto Lopes

Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1–positive advanced non–small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies

Kaname Nosaki, Hideo Saka, Yukio Hosomi et al. · Lung Cancer · 2019 · 278 citations

Pharmacy, Oncology, Pharmacotherapy +14

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Vivek Subbiah, Philippe A. Cassier, Salvatore Siena et al. · Nature Medicine · 2022 · 239 citations · Full text

Medicine, Oncology, Pharmacology +16

Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.

Gilberto Lopes, Yi‐Long Wu, Iveta Kudaba et al. · Journal of Clinical Oncology · 2018 · 192 citations

Medicine, Oncology, Pharmacotherapy +12

Treatment of Patients With Early-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline

Ainhoa Costas‐Chavarri, Govind Nandakumar, Sarah Temin et al. · Journal of Global Oncology · 2019 · 156 citations · Full text

Medicine, Oncology, Chemotherapy +12

Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer

Young Kwang Chae, Andrew A. Davis, Sarita Agte et al. · The Oncologist · 2019 · 125 citations · Full text

Medicine, Molecular Medicine, Oncology +17